Tag: clinical trial
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
New Phase 1 Trial Will Explore AQUA07 in ALK-positive NSCLC
Clinical Trial ID NCT07617337
-
Ivonescimab: A phase 2 Clinical Trial NCT07405190 by Akeso, Inc.
Clinical Trial ID NCT07405190
-
Patient Perspective: Hope for ALK+ NSCLC Patients
Jeff Sturm reflects on the emotional reality of living with ALK-positive cancer and the role gratitude, kindness, and community can play in helping patients and families hold onto hope.
-
-
Patient Perspective: Alternative Nuvalent drug for patients disqualified from NVL-655 due to liver toxicity
Jeff Sturm shares his experience accessing the investigational drug zidesamtinib through a single-patient IND after discontinuing the NVL-655 trial due to liver toxicity. His story highlights how physicians, researchers, and companies sometimes work together to explore additional options for patients.
-
ALK Positive funds two new clinical trials
November is Lung Cancer Awareness Month, which is a good time to reflect on our successes as an organization. In 2020, we were excited to announce that the ALK Positive/LUNGevity Research Fund will be funding clinical trials for the first time. It means that the money we have donated and raised is going directly toward…